Poseltinib

DB16299InvestigationalSmall molecule

Poseltinib is under investigation in clinical trial NCT02628028 (A Study of LY3337641 in Rheumatoid Arthritis).

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₂₆H₂₆N₆O₃ · 470.533 g/mol (avg)
Code names: HM71224 · LY3337641

Resolves to

Compound

Structure

InChIKeyLZMJNVRJMFMYQS-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=CC=C(NC2=NC(OC3=CC=CC(NC(=O)C=C)=C3)=C3OC=CC3=N2)C=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Poseltinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.